Antiplatelet therapy after endovascular intervention: Does combination therapy really work and what is the optimum duration of therapy?

Catheterization and Cardiovascular Interventions

Volumn 74, Issue SUPPL. 1, 2009, Pages

  Milani, Richard V ^a  

^a JOHN OCHSNER HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

Angioplasty; Atherothrombosis; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; PHENPROCOUMON; PLACEBO; TICLOPIDINE; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE;

ANKLE BRACHIAL INDEX; ARTERIOGRAPHY; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DRUG MEGADOSE; ENDOVASCULAR SURGERY; FEMOROPOPLITEAL BYPASS; FEMOROTIBIAL BYPASS; GRAFT OCCLUSION; GRAFT PATENCY; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HUMAN; INTERMITTENT CLAUDICATION; MONOTHERAPY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RISK REDUCTION; STENT; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; BLOOD VESSEL TRANSPLANTATION; CARDIOVASCULAR DISEASE; DRUG ADMINISTRATION; DRUG COMBINATION; EVIDENCE BASED MEDICINE; HEART INFARCTION; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; REVIEW; THROMBOSIS; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; VASCULAR PATENCY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; BLOOD VESSEL PROSTHESIS IMPLANTATION; CARDIOVASCULAR DISEASES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; GRAFT OCCLUSION, VASCULAR; HUMANS; MYOCARDIAL INFARCTION; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; THROMBOSIS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 70349229669     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21996     Document Type: Article

References (22)

1. Murphy TP, Soares G, Kim M. Increase in utilization of percutaneous renal artery interventions by Medicare beneficiaries, 1996-2000. AJR Am J Roentgenol 2004;183:561-568.
2. Stein PD, Dalen JE, Goldman S, Theroux P. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. Chest 2001;119(1 suppl):278S-282S.
3. Tangelder MJ, Lawson JA, Algra A, Eikelboom BC. Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery. J Vasc Surg 1999;30:701-709.
4. Kretschmer G, Herbst F, Prager M, Sautner T, Wenzl E, Berlakovich GA, Zekert F, Marosi L, Schemper M. A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis. Arch Surg 1992;127:1112-1115.
5. Becquemin JP. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine aprés Pontage Fémoro-Poplité and the Association Universitaire de Recherche en Chirurgie. N Engl J Med 1997;337:1726-1731.
6. Bergqvist D, Almgren B, Dickinson JP. Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: Results from the Swedish Ticlopidine Multicentre Study (STIMS). Eur J Vasc Endovasc Surg 1995;10:69-76.
7. Arcan JC, Blanchard J, Boissel JP, Destors JM, Panak E. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology 1988;39:802-811.
8. Goldhaber SZ, Manson JE, Stampfer MJ, LaMotte F, Rosner B, Buring JE, Hennekens CH. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study. Lancet 1992;340:143-145.
9. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
10. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-1655.
11. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, Koppensteiner R, Ergun E, Mittlboeck M, Schreiner W, Losert U, Wolner E. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997;78:1003-1007.
12. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA; AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-2372.
13. Mak KH, Belli G, Ellis SG, Moliterno DJ. Subacute stent thrombosis: evolving issues and current concepts. J Am Coll Cardiol 1996;27:494-503.
14. Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.
15. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting.Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-1671.
16. Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, Vrolix M, Missault L, Chierchia S, Casaccia M, Niccoli L, Oto A, White C, Webb-Peploe M, Van Belle E, McFadden EP. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) study. Circulation 1998;98:1597-1603.
17. Heiss HW, Just H, Middleton D, Deichsel G. Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. Angiology 1990;41:263-269.
18. Study Group on Pharmacological Treatment after PTA. Platelet inhibition with ASA/dipyridamole after percutaneous balloon angioplasty in patients with symptomatic lower limb arterial disease. A prospective double-blind trial. Eur J Vasc Surg 1994;8:83-88.
19. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533.
20. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ; CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288:2411-2420.
21. Mukherjee D, Topol EJ, Moliterno DJ, Brennan DM, Ziada K, Cho L, Steinhubl SR; CREDO Investigators. Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment. Heart 2006;92:49-51
22. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-1717.